Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GW Pharmaceuticals PLC

This article was originally published in Start Up

Executive Summary

GW is developing cannabis-based pharmaceuticals using extracts taken from plants which are specially bred to optimize the therapeutic benefit of cannabis.

You may also be interested in...

Pressure Is On Cannabinoid Drug Developer GW As Sativex Fails First Trial

GW Pharmaceuticals – a leader in development of cannabis plant-derived drugs – suffers setback with failure in its first Phase III study in cancer pain; results of two more studies are yet to be reported.

Social Norms Shift, But U.S. Rules On Cannabis-Related Drug R&D Lag Behind

While public, regulatory and law enforcement attitudes toward marijuana in the U.S. continue to shift, it’s still tough to pursue legitimate clinical research on cannabis and cannabinoids. Could the exceptions slowly become the rule?

Cannabis-Based Sativex Boosts Profits At GW Pharma

U.K. approval for Sativex breaks new regulatory ground, says company, clearing path for pipeline candidates.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts